Improving the lives of patients by combating metastatic cancer
We create innovative tools that provide deeper insights into cancer behaviour
The Vortex mission is to be the innovation leader in CTC capture technology that improves therapeutic decisions and saves lives
A New Window into Cancer Biology
Circulating tumour cells (CTCs) provide a real-time window into cancer biology; offering critical insights into the molecular and cellular mechanisms that drive the disease.
There is a major shift toward liquid biopsy in how cancer is studied and treated. As an innovation leader in Circulating Tumour Cell (CTC) capture technology, we’re helping researchers isolate and study circulating tumour cells — a key step in developing the next generation of anti-metastatic cancer therapies. Our advanced system offers a powerful tool to support more targeted and effective treatment development.
Circulating Tumour Cells Offer a Key Advantage
Circulating tumour cells (CTCs) provide real time insights into tumours progression. The analysis of CTCs can help to guide treatment decisions and improve patient outcomes.
Unlike circulating tumour DNA (ctDNA), CTCs are intact, viable cancer cells that provide real-time insights into tumour progression, evolution and treatment resistance. Their ability to deliver both molecular and functional information makes them invaluable for precision oncology.
VTX-1 Liquid Biopsy System
The Vortex VTX-1 Liquid Biopsy System simplifies and automates the isolation and collection of clinically relevant, viable CTCs directly from whole blood.
The great advantage to us of the Vortex technology is the rapid, gentle, non-contact isolation of live CTCs for our analysis. The Vortex VTX-1 rapidly isolates the live cells in excellent condition, which we simply couldn’t do by other methods.



